Back to Search
Start Over
Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m 6 A-YTHDF1-dependent manner.
- Source :
-
International journal of biological sciences [Int J Biol Sci] 2024 Sep 03; Vol. 20 (12), pp. 4750-4766. Date of Electronic Publication: 2024 Sep 03 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Patients with non-small cell lung cancer (NSCLC) are easily resistant to first-line chemotherapy with paclitaxel (PTX) or carboplatin (CBP). N <superscript>6</superscript> -methyladenosine (m <superscript>6</superscript> A) methyltransferase-like 3 (METTL3) has crucial functions in m <superscript>6</superscript> A modification and tumorigenesis. However, its role in chemoresistance of NSCLC is still elusive. Here, we demonstrated that METTL3 inhibitor STM2457 significantly reduced the IC <subscript>50</subscript> values of PTX or CBP in NSCLC cells, and they showed a synergistic effect. Comparing with monotherapy, a combination of STM2457 and PTX or CBP exhibited more potent in vitro and in vivo anti-tumor efficacy. In addition, we found that ATP binding cassette subfamily C member 2 (ABCC2) was responsively elevated in cytomembrane after PTX or CBP treatment, and targeting METTL3 could reverse this effect. Mechanistically, targeting METTL3 decreased the m <superscript>6</superscript> A modification of ABCC2 mRNA and accelerated its mRNA degradation. Further studies revealed that YTHDF1 could bind and stabilize the m <superscript>6</superscript> A-modified mRNA of ABCC2 , while YTHDF1 knockdown promoted it mRNA degradation. These results, taken together, demonstrate that targeting METTL3 enhances the sensitivity of NSCLC cells to PTX or CBP by decreasing the cytomembrane-localized ABCC2 in an m <superscript>6</superscript> A-YTHDF1-dependent manner, and suggest that METTL3 may be a potential therapeutic target for acquired resistance to PTX or CBP in NSCLC.<br />Competing Interests: Competing Interests: The authors have declared that no competing interest exists.<br /> (© The author(s).)
- Subjects :
- Humans
Cell Line, Tumor
Animals
Drug Resistance, Neoplasm genetics
Mice
Paclitaxel pharmacology
Paclitaxel therapeutic use
Mice, Nude
Carboplatin pharmacology
Carboplatin therapeutic use
Adenosine analogs & derivatives
Adenosine metabolism
Adenosine pharmacology
Carcinoma, Non-Small-Cell Lung metabolism
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung genetics
Multidrug Resistance-Associated Proteins metabolism
Multidrug Resistance-Associated Proteins genetics
RNA-Binding Proteins metabolism
RNA-Binding Proteins genetics
Methyltransferases metabolism
Methyltransferases genetics
Lung Neoplasms metabolism
Lung Neoplasms drug therapy
Lung Neoplasms genetics
Lung Neoplasms pathology
Multidrug Resistance-Associated Protein 2 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1449-2288
- Volume :
- 20
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- International journal of biological sciences
- Publication Type :
- Academic Journal
- Accession number :
- 39309428
- Full Text :
- https://doi.org/10.7150/ijbs.97425